Literature DB >> 9449632

Development of recombinant human prolactin receptor antagonists by molecular mimicry of the phosphorylated hormone.

T J Chen1, C B Kuo, K F Tsai, J W Liu, D Y Chen, A M Walker.   

Abstract

Previous studies have demonstrated that naturally phosphorylated PRL antagonizes the growth-promoting effects of unmodified PRL in two different PRL-responsive cell lines. In this study our aim was to produce a molecular mimic of phosphorylated PRL by substituting a fairly bulky, negatively charged amino acid (glutamate or aspartate) for the normally phosphorylated serine [serine 179 in human PRL (hPRL)]. In addition, because of the marked effect of phosphorylation on biological activity, we investigated the importance of the unmodified serine in the growth-promoting activity of PRL. hPRL complementary DNA was obtained from the American Type Culture Collection and subcloned into pT7-SCII after site-directed mutagenesis using the deoxyuridine approach. Proteins were expressed in Escherichia coli BL21 (DE3) and were primarily found in inclusion bodies. Agonist and antagonist activities of each serine 179 mutant were assessed using the Nb2 bioassay. Compared with standard hPRL, the recombinant wild-type was more active in the Nb2 assay, attesting to both the absence, or low level, of endotoxin contamination in preparations from these cells and the appropriate folding of the molecule. The aspartate and glutamate mutants had no intrinsic agonist activity, but both antagonized the growth-promoting activity of wild-type PRL, with the aspartate mutant proving to be a very effective antagonist. Two hundred picograms per ml of the aspartate mutant negated 75% of the growth response to 400 pg/ml wild-type PRL. When serine 179 was mutated to alanine or valine, mutant PRLs with 0% and 14% of the biological activity of wild-type PRL, respectively, were produced. These results demonstrate 1) that molecular mimicry of the phosphorylated hormone does produce a PRL antagonist, and 2) that the serine at position 179 is crucial to the growth-promoting activity of PRL. The aspartate mutant can now be used to study many aspects of the physiology of PRL.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9449632     DOI: 10.1210/endo.139.2.5758

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  22 in total

Review 1.  Paradigm-shifters: phosphorylated prolactin and short prolactin receptors.

Authors:  KuangTzu Huang; Eric Ueda; YenHao Chen; Ameae M Walker
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-25       Impact factor: 2.673

2.  An N-terminal splice variant of human Stat5a that interacts with different transcription factors is the dominant form expressed in invasive ductal carcinoma.

Authors:  Dunyong Tan; KuanHui E Chen; Changhui Deng; Peizhi Tang; Jianjun Huang; Trina Mansour; Richard A Luben; Ameae M Walker
Journal:  Cancer Lett       Date:  2013-12-30       Impact factor: 8.679

3.  Role of Prolactin in Promotion of Immune Cell Migration into the Mammary Gland.

Authors:  Riva Dill; Ameae M Walker
Journal:  J Mammary Gland Biol Neoplasia       Date:  2016-11-29       Impact factor: 2.673

4.  Prolactin blocks nuclear translocation of VDR by regulating its interaction with BRCA1 in osteosarcoma cells.

Authors:  Changhui Deng; Eric Ueda; Kuanhui E Chen; Craig Bula; Anthony W Norman; Richard A Luben; Ameae M Walker
Journal:  Mol Endocrinol       Date:  2008-12-12

5.  A mimic of phosphorylated prolactin inhibits human breast cancer cell proliferation via upregulation of p21 waf1.

Authors:  Wenjie Xie; Yan He; Da Huo; Yafang Huang; Wei Wu
Journal:  Med Oncol       Date:  2009-12-15       Impact factor: 3.064

6.  Site2 binding energetics of the regulatory step of growth hormone-induced receptor homodimerization.

Authors:  Scott T R Walsh; Liz M Jevitts; Juliesta E Sylvester; Anthony A Kossiakoff
Journal:  Protein Sci       Date:  2003-09       Impact factor: 6.725

7.  Enhancement of human prolactin synthesis by sodium butyrate addition to serum-free CHO cell culture.

Authors:  Herbert Rodrigues Goulart; Fernanda dos Santos Arthuso; Marcos Vinicius Nucci Capone; Taís Lima de Oliveira; Paolo Bartolini; Carlos Roberto Jorge Soares
Journal:  J Biomed Biotechnol       Date:  2010-06-16

8.  The rhythmic secretion of mating-induced prolactin secretion is controlled by prolactin acting centrally.

Authors:  Cleyde V Helena; De'Nise T McKee; Richard Bertram; Ameae M Walker; Marc E Freeman
Journal:  Endocrinology       Date:  2009-03-12       Impact factor: 4.736

9.  Common and specific effects of the two major forms of prolactin in the rat testis.

Authors:  Valencia L Williams; Ariel DeGuzman; Hong Dang; Mitsumori Kawaminami; Timothy W C Ho; David G Carter; Ameae M Walker
Journal:  Am J Physiol Endocrinol Metab       Date:  2007-10-02       Impact factor: 4.310

Review 10.  S179D prolactin: antagonistic agony!

Authors:  Ameae M Walker
Journal:  Mol Cell Endocrinol       Date:  2007-06-28       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.